Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A trial of withdrawal of nocturnal non-invasive positive pressure ventilation (NIPPV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic ventilatory failure previously stable on nocturnal NIPPV
ISRCTN ISRCTN00075564
ClinicalTrials.gov identifier
Public title A trial of withdrawal of nocturnal non-invasive positive pressure ventilation (NIPPV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic ventilatory failure previously stable on nocturnal NIPPV
Scientific title
Acronym N/A
Serial number at source 04/Q0104/139 - NRR Publication ID: N0542155456
Study hypothesis Currently it is unclear whether patients with severe COPD benefit from noninvasive positive pressure ventilation in the long term. There is divided opinion and evidence on whether this is a beneficial treatment and who might benefit. In performing this clinical trial of withdrawal of a non-proven treatment with close monitoring we plan to address the issue of whether of not the treatment does maintain the patients in a stable clinical state and improve their quality of life.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Chronic Obstructive Pulmonary Disease (COPD)
Participants - inclusion criteria Pre-screening criteria:
1. Diagnosis of COPD: forced expiratory volume in 1 second (FEV1) <50% predicted, FEV1/forced vital capacity (FVC) ratio <70%, total lung capacity (TLC) >80% predicted
2. Smoking history >20 pack years
3. Prior to commencing NIPPV hypercapnic ventilatory failure with daytime PaCO2 >7.5 kPa with normal pH (7.35-7.45) or nocturnal PtcCO2 >9 kPa
4. On NIPPV for at least 3 months with compliance of >4 hours/day
5. Live within 40-mile radius of trust

Screening criteria:
1. Clinically stable - no increase in breathlessness, cough or sputum volume in 4 weeks between initial assessment and entry to trial
2. PaCO2 within +/-1 kPa of initial assessment
3. No change in spirometry (<15% or 200 ml) from initial assessment
Participants - exclusion criteria 1. Age over 80
2. Other significant respiratory disease (interstitial lung disease, asthma, bronchiectasis, neuromuscular or restrictive chest wall disorders)
3. Significant documented left ventricular dysfunction with Ejection Fraction <40%
4. Obstructive sleep apnoea with an apnoea/hypopnoea index of over 10, which is reversible by continuous positive airway pressure (CPAP)
Anticipated start date 16/05/2005
Anticipated end date 31/01/2007
Status of trial Completed
Patient information material
Target number of participants 40
Interventions Comparison of withdrawing long term NIPPV treatment or continuing
Primary outcome measure(s) 'Withdrawal Failure' as stipulated by preset criteria. The effect of withdrawal of NIPPV therapy on arterial blood gas analysis.

Criteria for Withdrawal Failure:
1. Daytime PaCO2 >9 kPa
2. Nocturnal PtcCO2 >10 on night study
3. Respiratory acidosis pH <7.35
4. Intolerable symptoms, including morning headache and drowsiness
Secondary outcome measure(s) 1. Assess the effect of withdrawal of NIPPV therapy on: quality of life using SF-36 and St George's respiratory questionnaire, exacerbation rates, hospital admissions, GP contact and requirements for treatment with antibiotics and steroids
2. Assess that if preset criteria are met, reinstitution of NIPPV therapy has positive effects
3. Measure changes to spirometric, mouth pressure data and exercise capacity
Sources of funding Respiratory Support and Sleep Centre Trust fund supported by an unrestricted grant from B & D Electromedical (UK)
Trial website
Publications 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20397811
Contact name Dr  Nick  Oscroft
  Address Papworth Hospital NHS Trust
Papworth Everard
  City/town Cambridge
  Zip/Postcode CB3 8RE
  Country United Kingdom
  Tel +44 (0)1480 830541
  Fax +44 (0)1480 364568
  Email
Sponsor Papworth Hospital NHS Trust (UK)
  Address Papworth Everard
  City/town Cambridge
  Zip/Postcode CB3 8RE
  Country United Kingdom
  Tel +44 (0)1480 830541
  Fax +44 (0)1480 364568
  Email diane.bilton@papworth.nhs.uk
Date applied 23/05/2005
Last edited 16/07/2010
Date ISRCTN assigned 08/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central